Women's Hospital, Boston, MA Background:
Recurrent myocardial infarction (reMI). remains a limitation of fibrinolytic therapy. We hypothesized that following fibrinolytic administration, performance of percutaneous coronary intervention (PCI) during the index hospitalization is associated with lower rates of recurrent MI and death compared to conservative management. Methods: Performance of PCI thru hospital discharge and mortality up to 2 years were ascertained in the TIMI 4, 9A, 98, 106 and 17 acute Ml trials (n=20,043). Patients whose PCI followed a recurrent Ml (n=266) were included in the medical therapy arm. Results: PCI was performed in 21.4% of patients at a median of 4 days (IQ range l-6). In-hospital recurrent Ml occurred less frequently in patients treated with PCI vs. patients without PCI (1.6% vs. 4.5%, p<O.OOl). Mortality was also lower in patients treated with PCI (pc0.0001; Figure) . Similar results were seen across the low, intermediate, and high TIMI risk scores (Figure) . Both PCI and recurrent MI remained associated with 2 year mortality in a model adjusting for age, anterior MI. pulse on admission, and gender (PCI hazard ratio=0. 51 and 10.4% (StSK)(non-significant differences). Neither stroke nor other major haemoragical events were registered in the three subgroups. Simptomatic hypotansion was benign and appeared more frequent in the preASENOX (32%) and inASENOX (34%) subgroups as compared to the StSK one (20%).
Conclusions:
1. The preASENOX and inASENOX regimens are safe and lead toward a significant higher ratios of coronary repetfusion as compared to the StSK one. 2. Our data sugest a very low mortality in patients treated with the preASENOX regimenfurther investigation are needed for certify this attractive regimen. of pts seropositive for IgG against Cpcompared to 26% in pts being seronegative (p=ns). In the placebo group CE occurred in 23% IgG seropositive pts versus 47% in seronegative pts (p=O.O25). No significant treatment effects were also seen according to prevalence of IgA titers or in higher elevated titers. Conclusion:
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Left Ventricular Ejection Fraction, Enzyme Release, and Stent Implantation Are Independent Predictors of Late Clinical Outcome After Late Opening of Infarct-Related Occlusion
Neither seropositivity for C+I nor the amount of titer elevation was associated with a higher clinical event rate during 12 month of follow up after an acute myocardial infarction. Treatment with roxithromycin did not influence the rate of clinical events, independently of presence or amount of antibody titer elevation against Cp.
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Safety and Efficacy of an Accelerated Streptokinase Regimen in Combination With Enoxaparin in the Prehospital Management of the ST Acute Myocardial Infarction (ASENOX-2) Study
Gabriel Tatu 24 hours (hrs) and exposed to hypoxia (95%b-5%CO,) for 12 hrs followed by 12 hrs of m-oxygenation, or H9c2 cells were treated with EPO after hypoxia and before re-oxygenation. Also, 250mM hjOs for 22 hrs was used as an apoptotic stimulus. Cells were stained and analyzed for % apoptotic nuclei. To apply our findings in viva. we used a model of myocardial infarction (Ml) in rabbits. Animals were randomized to receive a single dose of EPO (5000 units/kg) or saline or sham (no Ml). On post-operative day (POD) 3, hemodynamic measurements were obtained. Hematocrits were drawn on POD 0, 1, 3, 
